Clinical trial · Observational
Immunogenicity and Safety of COVID-19 Vaccine in Cancer Patients
NCT04910295CI-TRIAL-00065563completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Serum antibody titre against COVID-19 spike protein will be measured before, after the first dose, and after the second dose (when applicable) in cancer patients who are receiving or received anti-cancer drugs. Side effects of vaccination and actual incidence of COVID-19 will be monitored.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer | Malignant Neoplasm | ALIAS | 0.90 |
| Covid19 | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| COVID-19 vaccine | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Antibody titre after vaccination
- timeFrame
- 21-28 days after completion of vaccination
- description
- Antibody titre as measured by Anti-SARS-CoV-2 ELISA (IgG)
Secondary outcomes (2)
- measure
- Antibody titer according to chemotherapy cycle, side effects, and use of corticosteroids or antipyretics
- timeFrame
- 21-28 days after completion of vaccination
- description
- Antibody titre as measured by Anti-SARS-CoV-2 ELISA (IgG)
- measure
- Incidence of COVID-19 infection
- timeFrame
- 6 months after completion of vaccination
- description
- Incidence of actual COVID-19 infection
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 20 Years
Show eligibility criteria text
Inclusion Criteria: * 20 years of age or older * Patients who are receiving or received anti-cancer drugs * Those who are not vaccinated against COVID-19 at the time of enrollment * Written informed consent Exclusion Criteria: * Any contraindications to COVID-19 vaccines * Those who were already vaccinated * Those who are on immunosuppressants or infected with HIV * Those who underwent organ transplantation * Active infections (for example, pneumonia)
References
Publications (0)
Data not yet available
No reference posted for this study.